ALVO

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Alvotech

NASDAQ | ALVO

5.61

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 7, 2025)

$1.58B

Market Cap

22

P/E Ratio

0.23

EPS

$13.70

52 Week High

$4.70

52 Week Low

HEALTHCARE

Sector

ALVO Chart

Recent Chart
Price Action

ALVO Technicals

Tags:

ALVO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $304M
Total Revenue $490M
Cost Of Revenue $185M
Costof Goods And Services Sold $185M
Operating Income $70M
Selling General And Administrative $61M
Research And Development $171M
Operating Expenses $235M
Investment Income Net -
Net Interest Income -$153M
Interest Income $4.6M
Interest Expense $158M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $31M
Income Before Tax -$218M
Income Tax Expense $14M
Interest And Debt Expense -
Net Income From Continuing Operations -$232M
Comprehensive Income Net Of Tax -
Ebit -$60M
Ebitda -$29M
Net Income -$232M

Revenue & Profitability

Earnings Performance

ALVO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $1.2B
Total Current Assets $455M
Cash And Cash Equivalents At Carrying Value $51M
Cash And Short Term Investments $51M
Inventory $128M
Current Net Receivables $252M
Total Non Current Assets $766M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $21M
Intangible Assets Excluding Goodwill $21M
Goodwill $11M
Investments -
Long Term Investments $0
Short Term Investments -
Other Current Assets $24M
Other Non Current Assets -
Total Liabilities $1.6B
Total Current Liabilities $193M
Current Accounts Payable $67M
Deferred Revenue -
Current Debt -
Short Term Debt $42M
Total Non Current Liabilities $1.4B
Capital Lease Obligations $122M
Long Term Debt $1B
Current Long Term Debt $33M
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.2B
Other Current Liabilities $68M
Other Non Current Liabilities -
Total Shareholder Equity -$413M
Treasury Stock -
Retained Earnings -$2.4B
Common Stock $2.8M
Common Stock Shares Outstanding $268M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$237M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $31M
Capital Expenditures $57M
Change In Receivables -
Change In Inventory -$50M
Profit Loss -
Cashflow From Investment -$19M
Cashflow From Financing $297M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$232M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $304M
Total Revenue $490M
Cost Of Revenue $185M
Costof Goods And Services Sold $185M
Operating Income $70M
Selling General And Administrative $61M
Research And Development $171M
Operating Expenses $235M
Investment Income Net -
Net Interest Income -$153M
Interest Income $4.6M
Interest Expense $158M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $31M
Income Before Tax -$218M
Income Tax Expense $14M
Interest And Debt Expense -
Net Income From Continuing Operations -$232M
Comprehensive Income Net Of Tax -
Ebit -$60M
Ebitda -$29M
Net Income -$232M

ALVO News

ALVO Profile

Alvotech Profile

Sector: HEALTHCARE

Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC

Alvotech Holdings SA is a pioneering biopharmaceutical company headquartered in Iceland, dedicated to the development and manufacturing of high-quality biosimilars aimed at enhancing patient access to critical biologic therapies. Utilizing advanced technology and a strong emphasis on research and development, Alvotech targets a diverse range of therapeutic areas to meet the increasing global demand for affordable medication alternatives. With its commitment to innovation and quality, the company is strategically positioned to become a leading player in the dynamic biosimilars market.

BKYI
+87.49%
$1.19
BIYA
+73.32%
$0.47
RUBI
+41.37%
$0.31
AZI
+0.70%
$0.09
NVDA
-1.27%
$185.68
BYND
-6.29%
$1.19
ASST
+1.03%
$1.46
ACHR
-13.90%
$7.64
MSGM
+58.44%
$3.47
VHAI
0.00%
$0.00
RIVN
-1.29%
$15.22
DNN
-4.11%
$2.56
TSLA
-2.94%
$432.79
PLUG
+2.39%
$2.57
PFE
-1.67%
$24.43
INTC
+0.46%
$37.41
AXDX
-61.36%
$0.03
ONDS
+8.47%
$5.69
SOFI
+0.64%
$27.33
WTO
-6.88%
$0.04
F
+0.45%
$13.18
BITF
-4.33%
$3.52
IREN
-12.36%
$66.95
AAPL
-0.13%
$269.77
ADAP
-15.14%
$0.05
IONZ
-7.99%
$3.80
WBD
-1.49%
$22.42
NIO
-5.56%
$6.76
PLTR
-0.41%
$174.32
CHR
-7.61%
$0.05
ETHD
-7.65%
$4.47
BURU
-0.22%
$0.27
NEHC
+6.52%
$6.04
MTVA
+7.41%
$0.91
DVLT
+11.02%
$1.51
AAL
+1.17%
$13.30
RGTI
-7.31%
$31.84
RMBL
+60.50%
$3.21
YDKG
-2.94%
$0.04
JOBY
-4.53%
$14.32
SNAP
+0.18%
$8.02
SOUN
+1.05%
$14.38
PBR
+4.84%
$12.72
RXRX
-6.85%
$4.62
ADD
-25.47%
$0.05
CAN
-12.40%
$1.12
MARA
-1.72%
$15.68
AMD
-3.72%
$228.84
T
-0.22%
$24.68
BTG
+3.55%
$3.93
SRM
+53.27%
$10.30
NVTS
-16.24%
$7.40
GRAB
-1.15%
$5.56
SMR
-7.79%
$29.92
CIFR
-4.44%
$20.74
QBTS
-2.09%
$27.79
ABEV
+1.45%
$2.43
HOOD
+0.89%
$128.21
KVUE
+2.35%
$16.84
RIG
+1.41%
$3.95
CCCS
-2.80%
$7.62
TLRY
+1.14%
$1.22
BMNR
+4.87%
$39.19
ORGO
+43.05%
$5.56
WLGS
-5.57%
$0.04
BTBT
+0.33%
$3.04
PRMB
-16.41%
$14.79
NOK
-1.30%
$6.82
ETWO
0.00%
$3.30
MTC
+1.80%
$2.82
BAC
+0.39%
$53.50
PLTZ
+0.70%
$7.15
GPUS
-1.99%
$0.36
FIG
-2.37%
$44.88
DKNG
+4.13%
$29.13
AMZN
-0.95%
$240.72
META
-2.67%
$618.94
WULF
-4.30%
$13.66
AFMD
-34.94%
$0.18
EPWK
+4.36%
$0.07
AMC
-6.74%
$2.42
QS
+1.66%
$16.16
CGC
+5.49%
$1.14
ELDN
-51.70%
$1.98
TTD
-7.58%
$42.42
MU
-2.52%
$232.32
VALE
-0.80%
$12.13
GOOGL
-2.47%
$277.69
IONQ
-4.49%
$54.85
KDLY
-10.01%
$0.72
QUBT
-6.19%
$12.33
RGTZ
+14.18%
$18.92
CLSK
-2.04%
$15.08
SMCI
-3.50%
$38.92
RR
-7.69%
$3.72
RF
+1.91%
$24.77
EOSE
+8.95%
$16.65
PLTD
+0.36%
$6.91
HIMS
-2.86%
$40.33
KLG
-9.05%
$13.35
BKYI
+87.49%
$1.19
BIYA
+73.32%
$0.47
RUBI
+41.37%
$0.31
AZI
+0.70%
$0.09
NVDA
-1.27%
$185.68
BYND
-6.29%
$1.19
ASST
+1.03%
$1.46
ACHR
-13.90%
$7.64
MSGM
+58.44%
$3.47
VHAI
0.00%
$0.00
RIVN
-1.29%
$15.22
DNN
-4.11%
$2.56
TSLA
-2.94%
$432.79
PLUG
+2.39%
$2.57
PFE
-1.67%
$24.43
INTC
+0.46%
$37.41
AXDX
-61.36%
$0.03
ONDS
+8.47%
$5.69
SOFI
+0.64%
$27.33
WTO
-6.88%
$0.04
F
+0.45%
$13.18
BITF
-4.33%
$3.52
IREN
-12.36%
$66.95
AAPL
-0.13%
$269.77
ADAP
-15.14%
$0.05
IONZ
-7.99%
$3.80
WBD
-1.49%
$22.42
NIO
-5.56%
$6.76
PLTR
-0.41%
$174.32
CHR
-7.61%
$0.05
ETHD
-7.65%
$4.47
BURU
-0.22%
$0.27
NEHC
+6.52%
$6.04
MTVA
+7.41%
$0.91
DVLT
+11.02%
$1.51
AAL
+1.17%
$13.30
RGTI
-7.31%
$31.84
RMBL
+60.50%
$3.21
YDKG
-2.94%
$0.04
JOBY
-4.53%
$14.32
SNAP
+0.18%
$8.02
SOUN
+1.05%
$14.38
PBR
+4.84%
$12.72
RXRX
-6.85%
$4.62
ADD
-25.47%
$0.05
CAN
-12.40%
$1.12
MARA
-1.72%
$15.68
AMD
-3.72%
$228.84
T
-0.22%
$24.68
BTG
+3.55%
$3.93
SRM
+53.27%
$10.30
NVTS
-16.24%
$7.40
GRAB
-1.15%
$5.56
SMR
-7.79%
$29.92
CIFR
-4.44%
$20.74
QBTS
-2.09%
$27.79
ABEV
+1.45%
$2.43
HOOD
+0.89%
$128.21
KVUE
+2.35%
$16.84
RIG
+1.41%
$3.95
CCCS
-2.80%
$7.62
TLRY
+1.14%
$1.22
BMNR
+4.87%
$39.19
ORGO
+43.05%
$5.56
WLGS
-5.57%
$0.04
BTBT
+0.33%
$3.04
PRMB
-16.41%
$14.79
NOK
-1.30%
$6.82
ETWO
0.00%
$3.30
MTC
+1.80%
$2.82
BAC
+0.39%
$53.50
PLTZ
+0.70%
$7.15
GPUS
-1.99%
$0.36
FIG
-2.37%
$44.88
DKNG
+4.13%
$29.13
AMZN
-0.95%
$240.72
META
-2.67%
$618.94
WULF
-4.30%
$13.66
AFMD
-34.94%
$0.18
EPWK
+4.36%
$0.07
AMC
-6.74%
$2.42
QS
+1.66%
$16.16
CGC
+5.49%
$1.14
ELDN
-51.70%
$1.98
TTD
-7.58%
$42.42
MU
-2.52%
$232.32
VALE
-0.80%
$12.13
GOOGL
-2.47%
$277.69
IONQ
-4.49%
$54.85
KDLY
-10.01%
$0.72
QUBT
-6.19%
$12.33
RGTZ
+14.18%
$18.92
CLSK
-2.04%
$15.08
SMCI
-3.50%
$38.92
RR
-7.69%
$3.72
RF
+1.91%
$24.77
EOSE
+8.95%
$16.65
PLTD
+0.36%
$6.91
HIMS
-2.86%
$40.33
KLG
-9.05%
$13.35
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.